Endocrine disorders: hypothyroidism,
switching from a progestin-only method such as an implant or injection: If you start taking LOESTRIN 24 Fe and you are
Metabolism The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week. Get Label RSS Feed, Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with Lo Loestrin Fe. Administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy [see Use in Specific Populations (8.1)]. Liver Disease 5. nausea does not go away, call your healthcare provider. necessitate the discontinuation of COC use until markers of liver function
Consider alternative contraception for women with uncontrolled dyslipidemias. Alternate contraceptive methods should be considered for women with uncontrolled dyslipidemia. are breastfeeding or plan to breastfeed. year they use LOESTRIN 24 Fe. mg/m² were excluded from the study. and refer to Day. multicenter clinical trial of LOESTRIN 24 Fe for contraception. COCs containing some synthetic estrogens (for example, ethinyl estradiol) may inhibit the metabolism of other compounds. remember. 77°F (20°C to 25°C).
other people. Stop LOESTRIN 24 Fe if there is unexplained loss of
0430-0420-95, These highlights do not include all the information needed to use, (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), Cigarette smoking increases the risk of serious cardiovascular, Advice in Case of Gastrointestinal Disturbances, Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment, Contraceptive Effectiveness Associated with Co-Administration of Other Products, Estradiol Associated with Co-Administered Drugs, Concomitant Use with HCV Combination Therapy – Liver Enzyme Elevation, in Plasma Levels of Co-Administered Drugs, Carcinogenesis, Mutagenesis, Impairment of Fertility, For this reason, COCs should not be used by w, ● Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations, During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as COCs.